SCHEMBL6277574

SCHEMBL6277574

O=C(CCC(O)=S)CN1C(=O)CCC1=O

nearest known ligand 0.41

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 3/20 0.40
RAB9A P51151 1/20 0.40
ALDH1A1 P00352 7/20 0.36
ALOX12 P18054 1/20 0.36
TSHR P16473 3/20 0.35
LMNA P02545 2/20 0.34
MEN1 O00255 2/20 0.33
KMT2A Q03164 2/20 0.33
GSK3A P49840 1/20 0.33
GSK3B P49841 1/20 0.33
HPGD P15428 2/20 0.33
S1PR2 O95136 1/20 0.32
GAA P10253 2/20 0.31
KDM4E B2RXH2 2/20 0.31
GFER P55789 1/20 0.31
POLB P06746 1/20 0.31
HTT P42858 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1269478 0.84 RAB9A (0.42) SMN1; SMN2RAB9AALDH1A1ALOX12TSHR
SCHEMBL871729 0.82 ALDH1A1 (0.44) SMN1; SMN2RAB9AALDH1A1ALOX12TSHR
SCHEMBL10015377 0.79 SMN1; SMN2 (0.41) SMN1; SMN2RAB9AALDH1A1ALOX12TSHR
SCHEMBL9614885 0.79 SMN1; SMN2 (0.43) SMN1; SMN2RAB9AALDH1A1ALOX12TSHR
SCHEMBL10673205 0.78 ALDH1A1 (0.40) SMN1; SMN2RAB9AALDH1A1ALOX12TSHR
SCHEMBL16405303 0.78 RAB9A (0.40) SMN1; SMN2RAB9AALDH1A1ALOX12TSHR
SCHEMBL11007672 0.77 LMNA (0.42) SMN1; SMN2RAB9AALDH1A1TSHRLMNA
SCHEMBL31440989 0.77 SLC22A6 (0.42) SMN1; SMN2RAB9AALDH1A1ALOX12TSHR
SCHEMBL19760179 0.76 GAA (0.42) SMN1; SMN2RAB9AALDH1A1ALOX12TSHR
SCHEMBL18825259 0.73 FAAH (0.40) SMN1; SMN2RAB9AALDH1A1ALOX12TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0941738-B1 Antigenic conjugates of conserved lipooligosaccharides of gram negative bacteria WYETH CORP (US) 2005-05-11 EP claimed
EP-0382781-B1 COMPOSITION FOR TREATING CANCERS CHARACTERIZED BY OVER-EXPRESSION OF THE C-FMS PROTO-ONCOGENE GENETICS INSTITUTE, INC. (US) 1993-09-29 EP claimed
EP-0863401-B1 Analytical test device with liquid-filled blister ROCHE DIAGNOSTICS GMBH (DE) 2002-08-28 EP disclosed
US-6159747-A Analytical test element with a blister filled with liquid ROCHE DIAGNOSTICS GMBH (DE) 2000-12-12 US disclosed
EP-0650054-B1 Process and device for obtaining and detecting immunologically reactive substances from the gas phase SECURETEC GMBH (DE) 2000-08-30 EP disclosed
EP-0863401-A1 Analytical test device with liquid-filled blister Roche Diagnostics GmbH (DE) 1998-09-09 EP disclosed
EP-0478715-B1 TARGETED LIPOSOMES AND METHODS FOR LIPOSOME-PROTEIN COUPLING LIPOSOME CO INC (US) 1996-04-03 EP disclosed
US-5419914-A Drug delivery VESTAR, INC. (US) 1995-05-30 US disclosed
EP-0650054-A2 Process and device for obtaining and detecting immunologically reactive substances from the gas phase Roche Diagnostics GmbH (DE) 1995-04-26 EP disclosed
US-5399331-A Drug delivery, medical diagnosis THE LIPOSOME COMPANY, INC. (US) 1995-03-21 US disclosed
EP-0555317-B1 PHOSPHOLIPID ANALOGUE VESICLE WITH A SUCCINIMIDYL MOIETY VESTAR INC (US) 1995-03-15 EP disclosed
EP-0555317-A1 PHOSPHOLIPID ANALOGUE VESICLE WITH A SUCCINIMIDYL MOIETY. VESTAR INC (US) 1993-08-18 EP disclosed
WO-1992005773-A1 PHOSPHOLIPID ANALOGUE VESICLE WITH A SUCCINIMIDYL MOIETY VESTAR, INC. (US) 1992-04-16 WO disclosed
WO-1991000289-A2 TARGETED LIPOSOMES AND METHODS FOR LIPOSOME-PROTEIN COUPLING THE LIPOSOME COMPANY, INC. (US) 1991-01-10 WO disclosed